Find the risk before the event. Then move it.

Sustained blood pressure elevation is silent and progressive - and it is the single largest treatable driver of stroke, heart attack, heart failure, and kidney disease. The aim of management is to get to target consistently, not to chase a perfect reading on a single day.

Diagnosis: confirmed by repeated readings under standardised conditions, often supplemented by home blood pressure monitoring or 24-hour ambulatory monitoring to rule out white-coat hypertension and identify nocturnal patterns.

Target ranges: typically <140/90 for most adults, with tighter targets (<130/80) for men with diabetes, established cardiovascular disease, or high calculated risk. Targets are individualised based on age, comorbidity, and tolerance.

First-line lifestyle: sodium reduction (<5 g/day), weight loss where overweight, regular aerobic exercise, alcohol moderation, and adequate sleep. Lifestyle alone can lower systolic blood pressure by 5-15 mmHg in motivated patients.

Medications: ACE inhibitors, ARBs, calcium channel blockers, and thiazide diuretics are first-line. Choice depends on comorbidity (diabetes, kidney function, prior cardiac events) and tolerability. Combination therapy is often more effective than monotherapy at higher doses.

Monitoring: home blood pressure log, repeat in-clinic reading at 4-6 weeks, then 3-monthly until stable. Annual review of kidney function, electrolytes, and overall cardiovascular risk.

Effectiveness: every 10 mmHg reduction in systolic blood pressure reduces major cardiovascular events by roughly 20% in men at elevated risk.

LDL cholesterol is the lipid metric most strongly tied to atherosclerosis. The level at which intervention becomes worthwhile depends on overall cardiovascular risk - not LDL alone, and not the lab report's generic reference range.

Workup: full fasting lipid profile (total cholesterol, LDL, HDL, triglycerides), and where indicated apolipoprotein B (the better target in men with metabolic syndrome or borderline LDL) and lipoprotein(a) (genetically determined, measured once in a lifetime - see our dedicated Lp(a) page).

Target LDL: <3.0 mmol/L for low-risk men; <2.6 mmol/L for moderate risk; <1.8 mmol/L for high risk or established disease; <1.4 mmol/L for very high risk (e.g. prior heart attack, diabetes with organ damage, familial hypercholesterolaemia).

Lifestyle: Mediterranean-style dietary pattern is the most evidence-based - vegetables, legumes, fish, olive oil, nuts, whole grains, with reduced ultra-processed food, added sugar, and saturated fat. Regular aerobic exercise modestly improves HDL and triglycerides.

Statins: first-line lipid-lowering therapy for men whose calculated risk justifies treatment. Most men tolerate statins well; muscle symptoms occur in a minority and are usually manageable with dose adjustment or rotation to a different statin.

Non-statin options: ezetimibe (added when statin alone doesn't reach target), PCSK9 inhibitors (for very high-risk men or statin-intolerant), bempedoic acid where available.

Monitoring: lipid recheck at 6-12 weeks after starting therapy, liver enzymes if symptoms, then annually once stable. Treatment is long-term: the benefit comes from sustained LDL reduction over years.

Read our full risk-stratified LDL targets guide for the specific numbers, how risk is calculated, and what the right plan looks like for your band: /cardiac-care/lipid-management.

Standard risk calculators (Framingham, ASCVD, SCORE2) put most middle-aged men in an intermediate band that the calculator alone cannot resolve. CT coronary imaging cuts through this ambiguity by showing the disease itself - plaque is either there or it is not - and reclassifies a meaningful share of intermediate-risk men, allowing prevention to be targeted rather than averaged.

CT coronary artery calcium score (CAC, Agatston): a quick, low-radiation, no-contrast scan that quantifies calcified plaque in your coronary arteries. Scored 0, 1-99, 100-399, or 400+. A zero score in a man over 45 typically defers statin therapy; a meaningful score reclassifies risk upward and triggers earlier, more aggressive prevention.

CT coronary angiogram (CTCA): contrast-enhanced CT that images the coronary lumen and the plaque itself, including non-calcified (soft) plaque that calcium scoring misses. Preferred in younger men with strong family history, when symptoms warrant direct visualisation, and as a non-invasive alternative to invasive angiography. Large trials (SCOT-HEART, PROMISE) have shown CTCA-guided care reduces non-fatal myocardial infarction over 5 years by getting the right men onto preventive therapy earlier.

How a CT result changes the plan: a CAC of zero may defer statin therapy and shift the recheck to 5 years; a CAC of 150 in the same man triggers statin therapy with a tighter LDL target, blood-pressure intensification and consideration of aspirin; non-calcified plaque on CTCA in a younger man with strong family history is treated as high-risk even when CAC is zero.

Direct-access ordering at Hisential: our MMC-registered medical team orders CAC and CTCA directly at partner hospitals without requiring a prior cardiologist consultation. Faster, lower total cost, and integrated into your wider plan. Specialist cardiology review is coordinated by your concierge if findings warrant it. See our dedicated CT coronary imaging page: /cardiac-care/ct-coronary-imaging.

The standard lipid panel misses two important risk signals. Apolipoprotein B (ApoB) counts the actual number of atherogenic particles, not just the cholesterol mass; in men with metabolic syndrome or borderline LDL, ApoB can be high when LDL looks fine. Lipoprotein(a) is a genetically determined particle that independently raises lifetime heart attack and stroke risk in roughly 1 in 5 people - and is essentially never measured in routine Malaysian general practice.

ApoB and the ApoB/ApoA1 ratio are added to the workup when metabolic features are present, or when standard LDL and the calculated risk give conflicting signals. They become the treatment target where the standard panel and ApoB disagree.

Lp(a) is measured once in a lifetime. The number itself does not respond meaningfully to lifestyle or statins, but an elevated result tightens every other cardiovascular target - especially LDL - and triggers cascade screening of first-degree relatives. See our dedicated Lp(a) page: /cardiac-care/lipoprotein-a.

Diabetes and prediabetes substantially amplify cardiovascular risk - men with type 2 diabetes have roughly twice the lifetime risk of heart attack and stroke. Identifying and treating metabolic dysfunction early reduces both microvascular and macrovascular outcomes.

Screening: HbA1c, fasting glucose, fasting insulin where indicated, BMI, waist circumference, and blood pressure together identify men along the spectrum from normal metabolism through prediabetes to type 2 diabetes.

Prediabetes management: lifestyle change is highly effective - structured dietary change and regular activity can reduce progression to type 2 diabetes by ~58% in motivated patients. Metformin is considered in higher-risk prediabetic men.

Established type 2 diabetes: HbA1c targets are individualised (typically <7% for most men, looser in older patients or those with comorbidity). Modern medications including GLP-1 receptor agonists (semaglutide, liraglutide) and SGLT2 inhibitors (empagliflozin, dapagliflozin) have specific cardiovascular benefits beyond glucose control and are preferred for men with established cardiovascular disease or high risk. See diabetes care.

Visceral fat reduction: 5-10% weight loss meaningfully shifts blood pressure, lipids, fasting glucose, and inflammatory markers. The number to aim for is sustainable, not dramatic. See weight loss for structured programmes.

Coordination: many men benefit from a coordinated plan covering blood pressure, lipids, glucose, and weight simultaneously - your personal health concierge ensures these don't get managed in isolation.

Reassessment: 3-monthly while making changes, then 6-12 monthly once stable.

The evidence-based interventions that actually move cardiovascular outcomes are also the most boring - and the most powerful. The role of the lifestyle protocol is to focus effort on the few interventions that genuinely shift risk, rather than spreading effort thinly.

Smoking cessation: the single largest reversible cardiovascular risk factor. Stopping at any age reduces risk substantially within months to years. Structured cessation support, including nicotine replacement and pharmacotherapy where indicated, is part of any first cardiac consultation for men who smoke.

Aerobic and resistance training: 150 minutes per week of moderate aerobic activity plus 2-3 weekly resistance sessions captures most of the cardiovascular benefit. More is better up to a point; the biggest gain is going from sedentary to consistent.

Mediterranean dietary pattern: vegetables, legumes, nuts, fish, olive oil, with limited ultra-processed food and added sugar. The dietary pattern with the strongest cardiovascular evidence. Specific superfoods, supplements, and elimination diets are mostly noise.

Sleep: 7-9 hours is the broad target. Sleep apnoea - common, often unrecognised in men with central adiposity, hypertension, or unrefreshing sleep - significantly raises cardiovascular risk and is worth screening for if there are clues (loud snoring, witnessed apnoeas, daytime fatigue).

Alcohol: no level of alcohol is cardioprotective at the population level. For men who drink, moderation (≤14 units per week, spread across multiple days, with alcohol-free days) limits risk.

Stress and mental health: chronic stress elevates cortisol, blood pressure, and inflammatory markers. Addressing it through structured approaches (exercise, sleep, social connection, professional support where needed) is part of cardiovascular care.

What is mostly a distraction: most antioxidant supplements, complicated fasting protocols pursued without metabolic indication, very expensive functional-medicine workups that produce many numbers and no plan.